Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Shares Repurchased (2023 - 2025)

Cytek Biosciences' Shares Repurchased history spans 3 years, with the latest figure at $80.8 million for Q4 2025.

  • For Q4 2025, Shares Repurchased rose 1054.29% year-over-year to $80.8 million; the TTM value through Dec 2025 reached $95.9 million, up 343.61%, while the annual FY2025 figure was $15.1 million, 30.25% down from the prior year.
  • Shares Repurchased reached $80.8 million in Q4 2025 per CTKB's latest filing, up from -$29000.0 in the prior quarter.
  • In the past five years, Shares Repurchased ranged from a high of $80.8 million in Q4 2025 to a low of -$29000.0 in Q3 2025.
  • Average Shares Repurchased over 3 years is $17.8 million, with a median of $8.4 million recorded in 2023.
  • The largest YoY upside for Shares Repurchased was 1054.29% in 2025 against a maximum downside of 100.24% in 2025.
  • A 3-year view of Shares Repurchased shows it stood at $34.6 million in 2023, then crashed by 79.77% to $7.0 million in 2024, then surged by 1054.29% to $80.8 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Shares Repurchased are $80.8 million (Q4 2025), -$29000.0 (Q3 2025), and $4.5 million (Q2 2025).